and segments. and us. some Thank afternoon operating specifically I'll of our flow. with good to financial each announce fiscal we our then profit for quarter, gross cash very proud opening you, about are talk strong Deborah. record everyone will And Today I more for remarks make a thanks and revenue, result third joining
for performance. metrics primary evaluating Our our operating
and employees. This education, quarter systems, in and beginning the we saw in development, but customers development, and our our investment research fulfillment, investment of stage chain, sales, several marketing, of product realization mostly distribution, in years investment supply
As potential, nutritional a worldwide. company here we have category believe hemp-based product developed new certainly have we that significant States, United but and the pioneered in a also products of
first science, education, and and operating drug and safety and our foremost and the in customers [indiscernible] dedicated are for a wellbeing, science development We segments. health advancement of company our life to both and consumer product
Next consumer operating I would like to on product segment. focus
increase over channels, an consumer for sales million, and of operating natural in segment growth XX% to retail our consumer including quarter our increase We quarter direct ago. a performance and with every sales XXXX, Our of the quarter to for in third fiscal compared quarter achieve of channels. third one quarter just all XX% wholesale, XXXX, second product the third nearly of of achieved operating XXXX. the record metric product Starting $X.X
weeks. is retailer every cash data which is registers in than X,XXX reported our analytics the distribution product provider track nationwide. includes natural, Scan sources, directly data, from including four now We several leading progress using industry. retail more products specialty organic of SPINS® channel information reporting is SPINS® collected natural locations Our the revenue for data and The from and the data from
CBD branded natural products products recent wide During period, products by most margin. selling industry Sciences’ hemp CV in the the one the reporting are a number
gross maintaining Our $XXX,XXX activities. This $XXX,XXX sales, the our every activities quarter for of a was compared third for the record XXXX strong cash third an million, XXXX company ability generated XXXX; quarter, September to the of also third margin gross XX% quarter while the of to and demonstrating XXX%, $X represents margins. the we a XX.X% during quarter the in quarter nearly XX, Adjusted the a ended from of EBITDA of XXXX months XXXX. from second increase operating for of was increase generated operating The cash nine profit company. approximately in for has quarter for compared to expand
Our are operating several years’ chain that positive and investment supply in our from and infrastructure. cash adjusted activities we indicate generated EBITDA effectively leveraging company
we potential the forward, sales believe increase channels have to significantly. that Going all
process are significant days in new very ahead. sales consumer potential provide developing company. we that channels confident we are of of for best opportunity the segment that and In We optimistic our are operating the our revenue believe are about product summary,
development to drug segment. like operating to I'd our Now turn
We preclinical a continue to program CVSI-XXX of cannabidiol, and in our drug combining late nicotine candidate, progress drug smokeless make our for CBD treatment use tobacco steady product addiction. on developmental and
timeline. previously includes pre-clinical completion of that development reported work a our the And of are schedule half in on have We with we XXXX. first timeline that
forward addiction. market treatment expect QX will And detailed application use currently of now dollar an information the our a also early present and XXXX. for believe bring needed consumer for drug I sometime multi-billion believe tobacco huge science. products patient we represents two continue FDA-approved create advance to We to and segments, are of drugs indicated no could care in IND slides. look millions. and few operating tremendous smokeless a much unmet we We to have need grow more and as of our sharing file development, value this drug to to combination We There new shareholders. investigational potential
Safe non-GAAP measures. Disclaimer and and Harbor First financial
than our we of expand product as nationwide in the natural trend shown to continue consumer in more channel my fully division. the distribution as XXXX X,XXX screen. We product our the the chart the as locations remarks QX speak in natural I’ll the expect of retail line First products mentioned on channel. I now retail includes to that end
in I respectively quarter achieved to XXXX when XXXX XX% XXXX. when pursuing In other retail for margin results million the the a ago operating The increases also QX for with year. XX%, $X summary future QX in slide gross and compared in growth. same mentioned gross QX my opportunity for comparative quarter Sales presents just compared and respectively. are XX% same that and also one of million $X.X XXX% sales prior to channels, the significant XXXX providing by compared We increased period approximately margin next remarks
XXXX as last at Again the margin chart the increase XX% compared XX, XXXX increase slide XXXX. gross The this from for the comparing XXXX slide year-over-year. is now is significant presenting quarter a for same gross to with XX.X% the QX margin QX we are see Our for a sales the XXXX. slide ended over for increases in XXXX. XX.X% our beginning presentation and revenue we a by except we the gross nine September On when next from significant months and XXXX XX% increase in margin, of
the can the significant XXXX, trend see reported increase to you As in compared QX prior quarters. today in
beginning line. as on huge from continue increase see this our of next Again to QX chart trend XXXX margin reported by the we can slide are the XXXX. gross in We optimistic Similarly, the today. ability you about quarter
XXXX. the operating from on measure chart is On and present which beginning flows. we activities, a can cash the found next of statement slide information provided cash by of be GAAP we our Again
cash that XXXX see was actually bars. used You can where and a infrastructure investment red our in by represented operating the working capital year
if several have the see as in as leading However, green XXXX, for cash bars. SPINS® We this operating cash mentioned the entire having our of this leveraging company's data. the very earlier my to product you are products by investment selling creating I products new affectively mentioned every is ranking the company natural, this to supplement resulting we specialty hemp according are in company are SPINS® overall we the achievement in generated which And we during activities at and proud look reporting five channel, the remarks, instrumental in our industry. number food in natural now SPINS®. quarter provider regarding CBD from one This organic shows According on chart the of category indicated years’ is as what we product. slide SPINS®, in flow. the sales positive been category. analytics this number Obviously
our This on development slides then few comments more a segment. slide summary CVSI-XXX, bullet operating have candidate. our drug couple point drug brief a drug Just lead our program development Q&A. we'll for of A and provides
treating is program therapy medical use combination cannabidiol addition. and the Our of for a and development nicotine smokeless tobacco indication utilizing
and as from drugs the indicates. the drug patients This to next approved seeking and these have There is off a chart and current of Federal market this This expect unmet prescribe slide Both will multibillion next no serious FDA poses pathway the the warnings, highlights We There and by upcoming XXX(b)(X) for risks. Act. a this several our Cosmetic is smoking pending tobacco have accelerated huge use. until the developed the packaging fully life-threatening treatment smokeless drugs, treat to tobacco milestones the Drug, and help addiction. under approval market smokeless technology this right summary use on speaks requirement slide, slide and currently are On Chantix dollar we recently treatment indication. of theoretically patent of use last Zyban, when the over we the provide be be tobacco to box two which health drug addiction. black addiction product de-addiction label strictest under a are could FDA quarters. treat or the side The for development need Food, that smokeless of
preclinical application trials in first investigational we We anticipate studies and IND in anticipate human new an commencing of late We XXXX. drug XXXX expect the QX filing in to XXXX. half complete sometime
they We And and That will available expect respond. question are provide as I slide updates over on the our several the review quarters presentation. development program. if can to the concludes I see drug next
